Platelet Microparticles: A Potential Predictive Factor of Survival in Hormone-Refractory Prostate Cancer Patients Treated with Docetaxel-Based Chemotherapy

Dominique Helley(Inserm), Stéphane Oudard(Assistance Publique – Hôpitaux de Paris), Abdelkader Bouziane(Hôpital Européen Georges-Pompidou), Anne‐Marie Fischer(Hôpital Européen), Adela Banu(Hôpital Européen), Eugéniu Banu(Hôpital Européen), Florian Scotté(Université Paris-Saclay)
European Urology
June 21, 2008
10.1016/j.eururo.2008.06.038
Cited by 106

Related Papers

Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
|The Lancet|2017|1.4k
Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial
|The Lancet Oncology|2021|645
ctDNA guiding adjuvant immunotherapy in urothelial carcinoma
|Nature|2021|603
Adjuvant atezolizumab versus observation in muscle-invasive urothelial carcinoma (IMvigor010): a multicentre, open-label, randomised, phase 3 trial
|The Lancet Oncology|2021|411
Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up
|Annals of Oncology|2020|319